1. Scrip
  2. >>Focus On Asia
  3. >>China

BeiGene's Brukinsa PFS Win Lifts China Biotech Stocks

Bests Imbruvica In CLL

 
• By Dexter Jie Yan

BeiGene's Brukinsa beats Imbruvica in top-line progression-free survival results from the Phase III head-to-head ALPINE trial in chronic lymphocytic leukemia or small lymphocytic lymphoma, marking the first time a rival BTK inhibitor has bested the same-class standard of care in this setting, and lifting the shares of other Chinese biotechs.

best in class concept
Prospects of a China innovative drug outdoing a global rival help sharp rebound in Chinese biotech shares • Source: Shutterstock

A final analysis from the global, head-to-head Phase III ALPINE trial with Nasdaq-, Hong Kong- and Shanghai-listed BeiGene, Ltd.'s Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) shows it beat Janssen Pharmaceuticals Inc./Pharmacyclics, Inc.’s same-class Imbruvica (ibrutinib) in terms of progression-free survival (PFS), a key secondary endpoint.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

New Data Strengthen Case For RemeGen’s Telitacicept In gMG

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

China Deal-Making Matures As Foreign Partners Derisk Asset Acquisition

 
• By Xu Hu

Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.

Vocal For ‘Glocal’: How Menarini Is Adapting To Outperform In The Asia Pacific

 
• By Anju Ghangurde

Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.

AZ’s Oncology R&D Head On China’s Scientific Promise And True Innovation

 
• By Dexter Jie Yan

AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.

More from Focus On Asia

What Is Fuelling Cell And Gene Therapies In India?

 
• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By Jung Won Shin

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.

AZ’s Oncology R&D Head On China’s Scientific Promise And True Innovation

 
• By Dexter Jie Yan

AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.